THE DEFINITIVE GUIDE TO BLUE CAPSULE TABLET

There was no solitary adverse response leading to discontinuation that occurred in a price of >2% in CAPLYTA-treated sufferers.Concomitant usage of CAPLYTA with reasonable or strong CYP3A4 inhibitors boosts lumateperone exposure [see CLINICAL PHARMACOLOGY], which can raise the chance of adverse reactions.The principal efficacy evaluate was the modi